Skip to main content
SpringerLink
Log in

Lymphoma Risk and Screening in IBD

  • Chapter
  • First Online:
Cancer Screening in Inflammatory Bowel Disease

  • 343 Accesses

Abstract

Our understanding of the risk of lymphoma in inflammatory bowel disease (IBD) is confounded by conflicting data, the impact of immunosuppressive medications on that risk, and the introduction of newer agents in the management of IBD. As we alter how we strategize, stratify, and combine therapies, this risk will also alter. Recent data is reassuring in downplaying the risk of lymphoma associated with anti-TNF therapies specifically and brings to the forefront legitimate concerns of thiopurine (6-MP, azathioprine) use, especially in young men. This chapter will discuss the impact of IBD and IBD therapies on overall lymphoma risk. We will also discuss the role of Epstein-Barr virus (EBV) in the development of lymphoma and our evolving understanding of the risk of hepatosplenic T-cell lymphoma (HSTCL) with IBD therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Eichenauer DA, Engert A, André M, et al. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii70–i5.

    Article  Google Scholar 

  2. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–52.

    Article  CAS  Google Scholar 

  3. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427–36.

    Article  CAS  Google Scholar 

  4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  Google Scholar 

  5. Horesh N, Horowitz NA. Does gender matter in non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014;5:e0038.

    Article  Google Scholar 

  6. Cancer stat facts: non-Hodgkin lymphoma. seer.cancer.gov. Accessed 9 Oct 2018.

  7. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.

    Article  Google Scholar 

  8. Taleban S, Elquza E, Gower-Rousseau C, Peyrin-Biroulet L. Cancer and inflammatory bowel disease in the elderly. Dig Liver Dis. 2016;48:1105–11.

    Article  Google Scholar 

  9. Afif W, Sandborn WJ, Faubion WA, et al. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013;19:1384–9.

    Article  Google Scholar 

  10. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:265–73.e1.

    Article  Google Scholar 

  11. Garg SK, Velayos FS, Kisiel JB. Intestinal and nonintestinal cancer risks for patients with Crohn’s disease. Gastroenterol Clin. 2017;46:515–29.

    Article  Google Scholar 

  12. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007;13:1299–307.

    Article  Google Scholar 

  13. Farrell R, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514–9.

    Article  CAS  Google Scholar 

  14. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080–7.

    Article  CAS  Google Scholar 

  15. Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308.

    Article  Google Scholar 

  16. Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer. 1992;69:1119–23.

    Article  CAS  Google Scholar 

  17. Garg SK, Loftus EV. Risk of cancer in inflammatory bowel disease: going up, going down, or still the same? Curr Opin Gastroenterol. 2016;32:274–81.

    Article  CAS  Google Scholar 

  18. van den Heuvel TR, Wintjens DS, Jeuring SF, et al. Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer. 2016;139:1270–80.

    Article  Google Scholar 

  19. Vos A, Bakkal N, Minnee R, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis. 2011;17:1837–45.

    Article  CAS  Google Scholar 

  20. Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol. 2005;56:169–78.

    Article  Google Scholar 

  21. Wheat CL, Clark-Snustad K, Devine B, Grembowski D, Thornton TA, Ko CW. Worldwide incidence of colorectal cancer, leukemia, and lymphoma in inflammatory bowel disease: an updated systematic review and meta-analysis. Gastroenterol Res Pract. 2016;2016:1632439.

    Article  Google Scholar 

  22. Shrestha MP, Ruel J, Taleban S. Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol. 2017;30:273.

    PubMed  PubMed Central  Google Scholar 

  23. Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19:1306–21.

    Article  Google Scholar 

  24. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018–24.

    Article  CAS  Google Scholar 

  25. Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. 2015.

    Book  Google Scholar 

  26. Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:621–31.

    Article  CAS  Google Scholar 

  27. McGovern DP, Travis SP. Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol. 2003;15:219–23.

    Article  CAS  Google Scholar 

  28. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146.

    Article  CAS  Google Scholar 

  29. Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.

    Article  CAS  Google Scholar 

  30. Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis. 2014;20:926–35.

    Article  Google Scholar 

  31. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.

    Article  CAS  Google Scholar 

  32. Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145:1007–15.e3.

    Article  CAS  Google Scholar 

  33. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.e4.

    Article  CAS  Google Scholar 

  34. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5:729–35.

    Article  Google Scholar 

  35. D’Haens G, Reinisch W, Panaccione R, et al. Lymphoma risk and overall safety profile of adalimumab in patients with Crohn’s disease with up to 6 years of follow-up in the pyramid registry. Am J Gastroenterol. 2018;1:872–82.

    Google Scholar 

  36. Andersen NN, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406–13.

    Article  Google Scholar 

  37. Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–51.

    Article  Google Scholar 

  38. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447–58.

    Article  CAS  Google Scholar 

  39. Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21:1847–53.

    Article  Google Scholar 

  40. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1464–78.e5.

    Article  Google Scholar 

  41. Chen Y, Friedman M, Liu G, Deodhar A, Chu C-Q. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine. 2018;101:78–88.

    Article  CAS  Google Scholar 

  42. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organisation: safety. Am J Gastroenterol. 2011;106:1594.

    Article  Google Scholar 

  43. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.

    Article  CAS  Google Scholar 

  44. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut. 2006;55:228–33.

    Article  CAS  Google Scholar 

  45. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn’s disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2010;17:758–66.

    Article  Google Scholar 

  46. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–8.

    Article  CAS  Google Scholar 

  47. Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901–14.e3.

    Article  Google Scholar 

  48. Miehsler W, Novacek G, Wenzl H, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohn’s Colitis. 2010;4:221–56.

    Article  CAS  Google Scholar 

  49. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212–7.

    Article  Google Scholar 

  50. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ registry. Am J Gastroenterol. 2014;109:212.

    Article  CAS  Google Scholar 

  51. Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:514–21.e4.

    Article  CAS  Google Scholar 

  52. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108:1835.

    Article  CAS  Google Scholar 

  53. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.

    Article  CAS  Google Scholar 

  54. Reijasse D, Le Pendeven C, Cosnes J, et al. Epstein-Barr virus viral load in Crohn’s disease: effect of immunosuppressive therapy. Inflamm Bowel Dis. 2004;10:85–90.

    Article  Google Scholar 

  55. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165–71.

    Article  CAS  Google Scholar 

  56. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72–7.

    Article  CAS  Google Scholar 

  57. Serrate C, Silva-Moreno M, Dartigues P, et al. Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn’s disease. Inflamm Bowel Dis. 2009;15:1449–51.

    Article  CAS  Google Scholar 

  58. Virdis F, Tacci S, Messina F, Varcada M. Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn’s disease. World J Gastrointest Surg. 2013;5:306–8.

    Article  Google Scholar 

  59. Münz C, Moormann A. Immune escape by Epstein-Barr virus associated malignancies. Semin Cancer Biol. 2008;18:381–7. Elsevier.

    Article  Google Scholar 

  60. Gordon J, Ramaswami A, Beuttler M, et al. EBV status and thiopurine use in pediatric IBD. J Pediatr Gastroenterol Nutr. 2016;62:711–4.

    Article  CAS  Google Scholar 

  61. Biank VF, Sheth MK, Talano J, et al. Association of Crohn’s disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr. 2011;159:808–12.

    Article  Google Scholar 

  62. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–9.

    Article  Google Scholar 

  63. Weinstock D, Ambrossi G, Brennan C, Kiehn T, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539.

    Article  CAS  Google Scholar 

  64. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohn’s Colitis. 2010;4:511–22.

    Article  Google Scholar 

  65. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.e1.

    Article  CAS  Google Scholar 

  66. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639.

    Article  Google Scholar 

  67. Mekelburg S, Schneider Y, Pizzi M, Chadburn A, Mathew S. The risk of hepatosplenic T-cell lymphoma (HSTCL) in women with inflammatory bowel disease (IBD) on thiopurines. J Inflam Bowel Dis Disord. 2016;1:110; 3:3

    Google Scholar 

  68. FDA. Hepatosplenic T-cell lymphoma. FDA adverse events reporting system (FAERS) 2018.

    Google Scholar 

  69. Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin. 2014;43:525–41.

    Article  Google Scholar 

  70. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99.

    Article  CAS  Google Scholar 

  71. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024–30.

    Article  Google Scholar 

  72. Dulai PS, Siegel CA, Colombel J-F, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014;63:1843–53.

    Article  CAS  Google Scholar 

  73. Aardoom MA, Joosse ME, de Vries ACH, Levine A, de Ridder L. Malignancy and mortality in pediatric-onset inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2018;24:732–41.

    Article  Google Scholar 

  74. Bernheim O, Colombel J-F, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut. 2013;62:1523–8.

    Article  CAS  Google Scholar 

  75. Axelrad J, Bernheim O, Colombel J-F, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:58–64.

    Article  CAS  Google Scholar 

  76. Beaugerie L, Carrat F, Colombel J-F, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416–23.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

    Chip Alex Bowman

  2. Columbia University Medical Center/NY-Presbyterian Hospital, New York, NY, USA

    Garrett Lawlor

Authors
  1. Chip Alex Bowman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Garrett Lawlor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Garrett Lawlor .

Editor information

Editors and Affiliations

  1. Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Joseph D. Feuerstein

  2. Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Adam S. Cheifetz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bowman, C.A., Lawlor, G. (2019). Lymphoma Risk and Screening in IBD. In: Feuerstein, J., Cheifetz, A. (eds) Cancer Screening in Inflammatory Bowel Disease . Springer, Cham. https://doi.org/10.1007/978-3-030-15301-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-15301-4_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-15300-7

  • Online ISBN: 978-3-030-15301-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation